A Newly Identified DNA Repair Switch Drives Resistance to PARP Inhibitors in Breast Cancer
Post Views: 111 A Newly Identified DNA Repair Switch Drives Resistance to PARP Inhibitors in Breast Cancer Targeted cancer therapies are designed to exploit specific weaknesses in tumor cells. One such treatment, PARP inhibitors, has transformed care for patients with breast cancers carrying BRCA mutations. These drugs work by blocking a DNA repair protein called…



